TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis

Tissue-agnostic indications for targeted therapies have expanded options for patients with advanced solid tumors. The Food and Drug Administration approvals of the programmed death-ligand 1 inhibitor pembrolizumab and the TRK inhibitors larotrectinib and entrectinib provide rationale for next-genera...

Descripción completa

Detalles Bibliográficos
Autores principales: Medford, Arielle J., Oshry, Lauren, Boyraz, Baris, Kiedrowski, Lesli, Menshikova, Sofia, Butusova, Anna, Dai, Charles S., Gogakos, Tasos, Keenan, Jennifer C., Occhiogrosso, Rachel H., Ryan, Phoebe, Lennerz, Jochen K., Spring, Laura M., Moy, Beverly, Ellisen, Leif W., Bardia, Aditya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893401/
https://www.ncbi.nlm.nih.gov/pubmed/36743521
http://dx.doi.org/10.1177/17588359231152844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893401/
https://www.ncbi.nlm.nih.gov/pubmed/36743521
http://dx.doi.org/10.1177/17588359231152844

Ejemplares similares